What is immunotherapy for testicular cancer

There are many new methods for treating testicular cancer, and many patients are therefore caught in a dilemma of choice. In fact, patients do not need to worry too much about which treatment method to choose, because doctors will develop a treatment plan suitable for patients based on their own conditions. Many people know about immunotherapy, so what is the immunotherapy for testicular cancer?

After being cultivated in a special GMP laboratory, activated and value-added cells are then infused back into the patient's body to systematically kill tumor cells. It is internationally recognized as the fourth new technology therapy that has the potential to completely eliminate tumors. Biological immunotherapy, also known as biological cell immunotherapy, is a "biological immunotherapy technology" developed by scientists in the field of cancer treatment at Temple University and Stanford University in the United States, who have found a breakthrough in the rapidly developing cytology and immunology. During treatment, two special functional cells are extracted from the human peripheral blood: dendritic cells are like "radars" that can actively search and identify tumor cells; killer cells with induction functions are like "missiles" that can accurately kill tumor cells without damaging any normal tissues.

Combining biological immunotherapy with radiotherapy can reduce the toxic and side effects of radiotherapy and increase the sensitivity of radiotherapy; combined with chemotherapy drugs, it can reduce the drug side effects in multiple systems such as digestion and blood, and enhance the inhibitory or killing effect on tumor tissue. The toxicity-reducing and synergistic effect of biological immunotherapy overcomes the shortcomings of the three traditional treatment methods of surgery, radiotherapy, and chemotherapy, such as "incomplete, easy to transfer, and large side effects". While accurately killing cancer cells, it can also repair and improve the patient's immune system, prevent spread and metastasis in all directions, and nearly double the 5-year survival rate.

The pathological type of testicular tumors is related to prognosis, and the extent of tumor spread and the range of metastasis also affect the prognosis. Therefore, clinicians should not only understand the pathological type of tumors, but also formulate corresponding treatment plans according to the different ranges of lesions. Therefore, it is of practical significance to determine the stage of each patient's lesion.